Search Results - "Pylypenko, Halyna"

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Authors: Grosicki, Sebastian Simonova, Maryana Spicka, Ivan et al.

Source: Lancet. 11/14/2020, Vol. 396 Issue 10262, p1563-1573. 11p.

Subjects: Research, Heterocyclic compounds, Dexamethasone, Research methodology, Antineoplastic agents, Organic compounds, Evaluation research, Medical cooperation, Drug administration, Comparative studies, Randomized controlled trials, Kaplan-Meier estimator, Multiple myeloma

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Authors: Moreau, Philippe Pylypenko, Halyna Grosicki, Sebastian et al.

Source: Lancet Oncology. May2011, Vol. 12 Issue 5, p431-440. 10p.

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Authors: Robak, Tadeusz Jin, Jie Pylypenko, Halyna et al.

Source: Lancet Oncology. Nov2018, Vol. 19 Issue 11, p1449-1458. 10p.

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Authors: Mateos, Maria V. Gavriatopoulou, Maria Facon, Thierry et al.

Source: Journal of Hematology & Oncology. 4/13/2021, Vol. 14 Issue 1, p1-5. 5p.

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study^*.

Authors: Robak, Tadeusz Huang, Huiqiang Jin, Jie et al.

Source: Leukemia & Lymphoma. Jan2019, Vol. 60 Issue 1, p172-179. 8p.

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.

Authors: Kipps, Thomas J. Eradat, Herbert Grosicki, Sebastian et al.

Source: Leukemia & Lymphoma. Oct2015, Vol. 56 Issue 10, p2826-2833. 8p.

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Authors: Chanan-Khan, Asher Cramer, Paula Demirkan, Fatih et al.

Source: Lancet Oncology. Feb2016, Vol. 17 Issue 2, p200-211. 12p.

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma.

Authors: Robak, Tadeusz Huiqiang Huang Jie Jin et al.

Source: New England Journal of Medicine. 3/5/2015, Vol. 372 Issue 10, p944-953. 10p. 3 Charts, 2 Graphs.

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Authors: Kiladjian JJ Klade C Georgiev P et al.

Corporate Authors: Kiladjian JJ Klade C Georgiev P et al.

Source: HemaSphere [Hemasphere] 2025 May 03; Vol. 9 (5), pp. e70137. Date of Electronic Publication: 2025 May 03 (Print Publication: 2025).

Publication Type: Letter

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.

Authors: Delimpasi S Mateos MV Auner HW et al.

Source: American journal of hematology [Am J Hematol] 2022 Mar 01; Vol. 97 (3), pp. E83-E86. Date of Electronic Publication: 2021 Dec 29.

Publication Type: Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Authors: Richard S Chari A Delimpasi S et al.

Source: American journal of hematology [Am J Hematol] 2021 Sep 01; Vol. 96 (9), pp. 1120-1130. Date of Electronic Publication: 2021 Jul 05.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Authors: Auner HW Gavriatopoulou M Delimpasi S et al.

Source: American journal of hematology [Am J Hematol] 2021 Jun 01; Vol. 96 (6), pp. 708-718. Date of Electronic Publication: 2021 May 03.

Publication Type: Comparative Study; Journal Article

Journal Info: Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE

The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.

Authors: Luke JJ Patel MR Blumenschein GR et al.

Source: Nature medicine [Nat Med] 2023 Nov; Vol. 29 (11), pp. 2814-2824. Date of Electronic Publication: 2023 Oct 19.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Authors: Gisslinger H Klade C Georgiev P et al.

Corporate Authors: Gisslinger H Klade C Georgiev P et al.

Source: Leukemia [Leukemia] 2023 Oct; Vol. 37 (10), pp. 2129-2132. Date of Electronic Publication: 2023 Aug 26.

Publication Type: Letter; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Authors: Kiladjian JJ Klade C Georgiev P et al.

Corporate Authors: Kiladjian JJ Klade C Georgiev P et al.

Source: Leukemia [Leukemia] 2022 May; Vol. 36 (5), pp. 1408-1411. Date of Electronic Publication: 2022 Feb 24.

Publication Type: Research Support, Non-U.S. Gov't; Letter

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

Authors: Gisslinger H Klade C Georgiev P et al.

Source: HemaSphere [Hemasphere] 2020 Oct 20; Vol. 4 (6), pp. e485. Date of Electronic Publication: 2020 Oct 20 (Print Publication: 2020).

Publication Type: Journal Article

Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Authors: Gisslinger H Klade C Georgiev P et al.

Corporate Authors: Gisslinger H Klade C Georgiev P et al.

Source: The Lancet. Haematology [Lancet Haematol] 2020 Mar; Vol. 7 (3), pp. e196-e208. Date of Electronic Publication: 2020 Jan 31.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study.

Authors: Verhoef G Robak T Huang H et al.

Source: Haematologica [Haematologica] 2017 May; Vol. 102 (5), pp. 895-902. Date of Electronic Publication: 2017 Feb 09.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Authors: Moreau P Pylypenko H Grosicki S et al.

Source: Haematologica [Haematologica] 2015 May; Vol. 100 (5), pp. e207-10. Date of Electronic Publication: 2015 Jan 16.

Publication Type: Clinical Trial, Phase III; Letter; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.

Authors: Arnulf B Pylypenko H Grosicki S et al.

Source: Haematologica [Haematologica] 2012 Dec; Vol. 97 (12), pp. 1925-8. Date of Electronic Publication: 2012 Jun 11.

Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE